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INTRODUCTION
At present, the number of patients with cerebrovascular 
diseases is steadily increasing. Increasingly, 
cerebrovascular accident occurs in able bodied and 
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socially active middle-aged people. In recent years, the 
study of various aspects of cerebrovascular pathology 
has significantly intensified, which led to significant 
progress in the prevention, treatment, and recovery after 
a stroke, as well as to reduce the mortality from this 
disease.[1] However, despite the availability of a wide 
range of modern drugs for stroke pharmacotherapy, the 
outcome of the disease remains extremely unfavorable – 
the increasingly cerebrovascular accident remains one of 
ABSTRACT
Introduction: The study was to investigate the ethylthiadiazole derivative with the (code LHT 4–15) for the presence of 
neuroprotective effects. Materials and Methods: The study was performed on male rats of the Wistar line. The animals were 
simulated with total cerebral ischemia with preliminary administration of LHT 4–15 compounds in doses of 25 and 50 mg/kg 
for 60 min. The degree of neurological deficiency and the behavioral status of the animal was studied. In the experiment, 
five groups of rats (n = 10) were isolated: (1) intact, (2) pseudo-operated, (3) with total cerebral ischemia, (4) with total 
cerebral ischemia and 60 min LHT 4–15 in a dose of 25 mg/kg, and (5) with total cerebral ischemia and a preliminary dose 
of 50 mg/kg in 60 min. In the work, a pathology model was used in which a temporary occlusion of two common carotid 
arteries was performed for 4 min, with preliminary coagulation of two vertebral arteries. The protocol of the study included the 
following stages: Modeling of cerebral ischemia; evaluation of the electroencephalogram level of the animal; and assessment 
of behavioral status (2 days) and neurological deficit at 1, 3, 7, and 14 days after modeling pathology. The blood of rodents was 
investigated in the contents of s100b and neuron-specific enolase (NSE). Results: The introduction of LHT 4–15 at a dose of 25 
and 50 mg/kg limited the development of neurologic deficits (P < 0.05). After 1 day, the average neurological ball in the group 
with the administration of LHT 4–15 at a dose of 25 mg/kg was 1.8 ± 0.11, and when 50 mg/kg was administered 0.7 ± 0.09. In 
the behavioral test “elevated cross-shaped labyrinth” of a group of rats with cerebral ischemia and preliminary administration 
of LHT 4–15 at a dose of 25 mg/kg and 50 mg/kg, they showed themselves more actively compared to the control group. This 
manifested itself in an increase in horizontal and vertical activity, which was reflected in more racks and stilts. The estimated 
research behavior declined, but insignificantly (P < 0.05). When assessing the motor activity of animals in the actinometry 
test with infrared (IR) monitoring of the IR Actimeter activity, a group of rats with the administration of LHT 4–15 at a dose 
of 25 mg/kg showed an activity slightly higher than the group administered with the compound at a dose of 50 mg/kg. Groups 
of animals with the preliminary administration of LHT 4–15 at doses of 25 and 50 mg/kg were more active, developed a 
high speed, and passed a longer distance. The rest time in these groups is lower in comparison with the control (P < 0.05). 
When analyzing the level of S100b and NSE in animals of the group with cerebral ischemia, with a preliminary introduction 
of 2-amino-5-ethyl-1,3,4-thiadiazole glee-cyclizine at a dose of 50 mg/kg there was a decrease in the levels of markers in 
Virginia even below the level of the control group (P > 0.05). Correction of ischemic injury 2-amino-5-ethyl-1,3,4-thiadiazole 
a glycylglycine showed a statistically significant increase in resistance of neurons in the frontal lobe and CA1 region of the 
hippocampus to hypoxia and ischemia, a significant decrease in the number of dead neurons and the high activity of reparative 
processes. Conclusion: The data obtained from the neurological deficit and in the behavioral tests of the experimental groups 
confirm the theory of the presence of ethylthiadiazole derivatives under the LHT code 4–15 neuroprotective properties.
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the leading causes of death, and the majority of patients 
who have had a stroke permanently remain disabled. 
Moreover, there is currently no universally recognized 
neuroprotection program that has proven effective 
in improving the outcome of the disease. Therefore, 
the search for new compounds with pronounced 
cytoprotective[2-5] and specific neuroprotective[6-8] activity 
becomes is one of the top priorities in pharmacology. 
The main focus of research development is focused on 
oxidative stress,[9-12] nitrogen oxide imbalance,[13-16] and 
intracellular secondary messengers.[17,18]
Ethylthiadiazole derivatives have a wide spectrum of 
pharmacological activity, including neuroprotective 
effects.[19,20] Among them, there are a large number 
of compounds with anti-inflammatory, antimicrobial, 
anticonvulsant, antihypertensive, antioxidant, and 
antitumor effect.[21,22] The expressed biological activity 
of these compounds is due to their chemical structure, 
in fact, thiadiazoles are heterocyclic compounds based 
on a ring five-membered heterocycle containing two 
nitrogen atoms and a sulfur atom.
MATERIALS AND METHODS
The study was performed on 50 mature male Wistar 
rats of 5–6-month-old age weighing 180–210 g. The 
content of animals met all the rules of laboratory 
practice during pre-clinical studies in the territory 
of the Russian Federation. The animals were kept 
in standard conditions that corresponded to sanitary 
rules (No. 1045-73) approved by the Union of Soviet 
Socialist Republics Ministry of Health on April 6, 1977 
for the arrangement, equipment, and maintenance of 
experimental biological clinics (vivaria) and GOST R 
53434-2009. Vivisection was carried out according to 
the ethical principles of handling laboratory animals. 
“The European Convention for the protection of 
vertebral animals used for experimental and other 
scientific purposes, CETS No.123”.
In the experiment, five groups of rats (n = 10) were 
isolated: (1) Intact, (2) false-operated, (3) with total 
cerebral ischemia, (4) with total cerebral ischemia 
and 60 min LHT 4–15 in a dose of 25 mg/kg, and 
(5) with total cerebral ischemia and a preliminary dose 
of 50 mg/kg in 60 min. LHT 4–15 was administered 
intragastrically through the probe. This compound was 
synthesized in JSC “All-Russian Center for the study 
of the safety of biologically active substances” (All-
Russian Scientific Center for the Safety of Biologically 
Active Substances, Russia, Staraya Kupavna).
Animalization of animals in the experiment was 
performed using zoletil 60 mg/kg and chloral hydrate 
150 mg/kg.
All experiments were performed in accordance with 
the methodological recommendations for preclinical 
study of drugs in cases of cerebral circulation 
disorders. In the work, a pathology model was used in 
which a temporary occlusion of two common carotid 
arteries was performed for 4 min, with preliminary 
coagulation of two vertebral arteries. Assessment of 
the adequacy of occlusion of arteries supplying blood 
to the brain was performed by recording the electrical 
activity of the brain of the animal on a Biopac 
Systems Inc. device MP150 electroencephalogram 
(EEG100C). The method was carried out with the 
help of the program AcqKnowledge 4.2. The criterion 
of a correctly executed technique was a decrease in 
the amplitude of the EEG.
The protocol of the study included the following 
stages: Modeling of cerebral ischemia; evaluation of 
the EEG level of the animal; assessment of behavioral 
status (2 days); and neurological deficit at 1, 3, 7, and 
14 days after modeling pathology.
To evaluate the neurological status of rats, several 
methods were used: (1) The scale of the McGraw 
stroke assessment in the modification of I.V. 
Gannushkina. Within the group of rats with signs 
of neurologic deficiency were divided into animals 
with mild, moderate, and severe symptoms of 
neurologic deficiency. If the animal was present 
with several signs of a neurological deficit, then the 
scores were summarized. (2) “Elevated cross-shaped 
labyrinth” – a behavioral test for studying the activity, 
emotional state, and level of anxiety of laboratory 
animals during the experiment. The experiment used 
a labyrinth installation of Panlab Harvard Apparatus 
LE 846.3. “Infrared (IR) activity monitor” – IR 
Actimeter allows performing testing of voluntary 
motor activity, the number and duration of hitching 
episodes, stereotyped movements, and exploratory 
behavior in the “perforated field” model under 
daylight and nighttime conditions used to assess 
the orienting research behavior. In the experiment, 
we used the Panlab Harvard Apparatus LE 8825 
installation. The blood of rodents was investigated 
in the contents of s100b and neuron-specific enolase 
(NSE).
For all data, descriptive statistics were applied. 
The obtained data were checked for the normal 
distribution. Using the Shapiro–Wilk criterion, the 
type of distribution was chosen. In the case of a normal 
distribution, the average value of M and the standard 
error of the mean m was calculated. In cases of abnormal 
distribution, the median Me and the QR-range were 
calculated. Intergroup differences were analyzed 
by parametric (student’s t-test) or non-parametric 
(Mann–Whitney test) methods, depending on the type 
of distribution. Differences were determined at 0.05 
significance level. Statistical analysis is performed 
using the software Statistica 10.0.
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RESULTS AND DISCUSSION
For the control, the data received from animals with 
total cerebral ischemia were accepted. In assessing 
the severity of the neurological deficit by McGraw in 
the modification of I.V. Gannushkina after modeling 
ischemia, after 1 day, the average ball was high 3.95 ± 
0.57, which is due to the presence of symptoms such as 
lethargy and slowed movements, one-sided half ptosis 
of the right eye. In 20% of the animals, a death was 
recorded. Sluggishness and slowness of movements 
to day 3 after modeling pathologies disappeared. At 
3, 7, and 14 days, a semiptosis of the right eye was 
preserved.
The introduction of LHT 4–15 at a dose of 25 mg/kg 
limited the development of neurological deficits. After 
1 day, the average neurological ball was 1.8 ± 0.11. The 
neurological deficit manifested itself in sluggishness 
and slowness, movements, and unilateral half ptosis of 
the right eye. The percentage of rats with semiptosis 
was lower than in the group of rats with ischemia. 
Fixation of 10% of the lethal outcome sluggishness 
and slowness of movements to day 3 after modeling 
the pathology disappeared (P < 0.05). Compared with 
the control, the animals of this group were very active 
even in the 1st day after modeling the pathology.
The introduction of LHT 4–15 at a dose of 50 mg/kg 
also limited the development of neurological deficits. 
After 1 day, the average neurological score 
was 0.7 ± 0.09. The neurological deficit manifested 
itself in sluggishness and slowness, movements, and 
unilateral half ptosis of the right eye. Sluggishness 
and slowness of movements to day 3 after modeling 
pathologies disappeared. In this group, mortality was 
not observed in animals (P < 0.05) [Table 1].
Thus, the preliminary administration of LHT 4–15 at a 
dose of 25 mg/kg and 50 mg/kg significantly (P < 0.05) 
decreased the number and/or severity of neurologic 
symptoms in animals after pathology modeling. 
A more pronounced effect was observed when the 
compound was administered at a dose of 50 mg/kg.
The behavioral status of the rats was assessed using the 
test “elevated cross-shaped labyrinth” [Table 2]. In the 
group with a four vascular 4-min cerebral ischemia, a 
Table 1: Effect of LHT 4–15 on the dynamics of the severity of neurologic disorders in rats with cerebral ischemia by 
McGraw in the modification of I.V. Gannushkina (1996) (based on the average score in the group) (M±m; n=10)
Groups Time
1 day 3 day 7 day 14 day
Intact 0 0 0 0
Pseudo-operated 0 0 0 0
Pathology 3.95±0.57 2.75±0.29 2.4±0.27 2.3±0.21
LHT 4–15 25 mg/kg 1.8±0.11* 1.75±0.14* 1.3±0.08* 1.1±0.1 9*
LHT 4–15 50 mg/kg 0.7±0.09* 0.6±0.12* 0.3±0.10* 0.3±0.10*
Here and elsewhere * - P<0.05 in relation to the control
Table 2: Effect of LHT 4–15 on the behavioral activity of animals with cerebral ischemia in the test “elevated 
cross‑shaped labyrinth” (M±m; n=10)
Criterion Groups
Intact False‑operated Control LHT 4‑15 25 mg/kg LHT 4‑15 50 mg/kg
Dark sleeve, t 86.8±12.3 120±7.1 167.3±2.9 118±10.7* 129±7.3*
Light sleeve, t 93.2±12.3 60±7.1 12.7±2.9 64.7±11.8* 51.4±7.3*
Racks, pieces 5.8±0.6 4.4±0.7 2.9±0.5 5.1±0.5* 4.9±0.9*
Sewing, pieces 6.9±0.7 4.9±0.3 1±0.2 4.5±0.4* 3±0.5*
Table 3: Effect of LHT 4–15 on the behavioral activity of animals with cerebral ischemia in the actinometry 
test (M±m; n=10)
Criterion Groups
Intact Pseudo‑operated Pathology LHT 4–15 25 mg/kg LHT 4–15 50 mg/kg
General activity, 
у.е.
775±52.02 688.8±29.87 451.9±45.05* 598.9±27.37* 565.1±45.60*
Stereotypes of 
motion, у.е.
73.1±2.71 55.2±4.56 27.4±3.00* 33.2±2.51* 38.4±3.52*
Maximum speed, 
у.е.
34.57±1.82 30.29±2.17 20.88±1.68* 23.08±1.40* 26.68±1.51*
Total distance, 
у.е.
1497.14±36.67 1386.8±51.25 756.30±72.11* 983.78±51.92* 1055.92±124.76*
Time of rest, у.е. 75.53±13.23 98.15±6.02 162.17±17.17* 136.88±10.14* 129.7±13.52*
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significant decrease in horizontal activity was observed 
in animals, an increase in the time spent in the dark 
sleeves. Reduction of vertical activity was manifested 
in the reduction of the posts, hanging by approximately 
75%. The minimal orienting research behavior remained. 
In the behavioral test “elevated cross-shaped labyrinth” 
of a group of rats with pathology and preliminary 
administration of LHT 4–15 at a dose of 25 mg/kg and 
50 mg/kg, they showed themselves more actively than 
the control group. This manifested itself in an increase 
in horizontal and vertical activity, which was reflected in 
more racks and stilts. The estimated research behavior 
declined, but insignificantly (P < 0.05). A group of 
rats with the administration of LHT 04–15 at a dose of 
25 mg/kg exhibited an insignificantly higher activity 
compared to the group administered with 50 mg/kg.
When assessing the motor activity of animals in the 
actinometry test with IR monitoring of the IR Actimeter 
activity after the pathology modeling, the activity of the 
rats dropped: General activity decreased, the number 
of stereotyped motions, the maximum speed, and the 
total distance. The rest time, in comparison with the 
false-operated ones, increased [Table 3].
Groups of animals with the preliminary administration 
of LHT 4–15 at doses of 25 and 50 mg/kg were more 
active, developed a high speed, and passed a longer 
distance. The rest time in these groups is lower in 
comparison with the control (P < 0.05) [Table 3].
Then, the level of s100b and NSE neuron-specific 
markers in these groups was monitored. In the 
analysis of S100b and NSE levels in animals of these 
experimental groups, an increase in the concentration 
of markers in serum was recorded. A statistically 
insignificant (P > 0.05) increase in the concentration 
of markers was observed in falsely operated animals. 
Statistically significant (P < 0.05) was an increase in 
the concentration in the group with 4-min and cerebral 
ischemia. When analyzing the level of S100b and 
NSE in animals of the group with cerebral ischemia, 
with a preliminary introduction of LHT 4–15 at a dose 
of 50 mg/kg, there was a decrease in the levels of 
markers in Virginia even below the level of the control 
group (P > 0.05). [Table 4].
Thus, the results indicate a pronounced correction of 
ischemic brain damage in the conditions of total four-
vascular model of cerebral ischemia in rats LHT 04–
15 at a dose of 50 mg/kg of body weight of the animal 
with a single intragastric administration.
CONCLUSION
Thus, the data obtained from the neurological deficit 
and in the behavioral tests of the experimental groups 
confirm the theory of the presence of ethyl thiadiazole 
derivatives under the LHT code 4–15 neuroprotective T
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properties. In the group of rats with the administration 
of the substance in a dose of 50 mg/kg, the effect 
is more pronounced. In a group of rats with the 
management of LHT 4–15 at a dose of 25 mg/kg, the 
neuroprotective effect was also observed, but less 
pronounced. In this regard, it can be assumed that 
LHT 4–15 has antioxidant and antihypoxic activity 
and blocks activation of free radical processes, as 
well as lipid peroxidation of cell membranes that 
occur during the development of acute myocardial 
infarction, ischemic and hemorrhagic strokes, acute 
violations of regional, and general blood circulation. 
The level of neuron-specific markers confirms it.
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